Immatics, a specialist in the field of cancer immunotherapy, announced the appointment of Thomas Ulmer as Chief Financial Officer (CFO), effective 1 April 2018.
Ulmer joins Immatics from the Merck Group, where he is currently Chief Financial Officer of the Allergopharma Business Unit.
Ulmer began his professional career with Merck in 2004 and has held a number of roles, including Head of Business Planning & Analysis and previously Head of Planning, Forecasting & Resource Allocation for the Merck Group.
He has also been Chief Financial Officer for Australia / New Zealand and Financial Controller for Merck’s global generics business. Ulmer is a Certified Practising Accountant and holds an MBA.
Peter Chambré, Chairman of Immatics, said: “We are delighted that Thomas is joining Immatics as our CFO. He will bring his exceptional financial expertise and experience to Immatics at a key time in the Company’s development. Building on our world-leading T-cell receptor (TCR) and target discovery platform XPRESIDENT, we currently have a number of adoptive cellular therapy clinical trials underway, with more expected to commence in 2018.”
“We are also progressing our pipeline of proprietary Bispecific TCR candidates. As we develop Immatics for the future, Thomas will be a key member of the Management team executing our strategy and advancing our broad portfolio of immunotherapies for the treatment of cancer.”
Thomas Ulmer, Chief Financial Officer of Immatics, said: “I am thrilled to be joining Immatics at this exciting time in its development, with several clinical trials of Immatics’ adoptive cellular therapies underway and plans in place to grow the pipeline in the coming years.”
“Immatics has unique and impressive proprietary technologies and I look forward to contributing to the future of the Company, as it sets about its goal to change the course of cancer for patients.”
